×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Novo Nordisk's Stance on Semaglutide for Cosmetic Use
Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in SOUL Trial
Rybelsus® Cuts Cardiovascular Risk by 14% in SOUL Trial
Articles
Articles
All News
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
September 2025
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Dexcom Introduces Smart Basal at EASD 2025
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
August 2025
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Teva Launches First Generic GLP-1 for Obesity
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Signos Press Release Raises Questions About FDA Clearance Claims
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
FDA Approves Wegovy for MASH Treatment
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
July 2025
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
